JP2024091777A5 - - Google Patents
Info
- Publication number
- JP2024091777A5 JP2024091777A5 JP2024066552A JP2024066552A JP2024091777A5 JP 2024091777 A5 JP2024091777 A5 JP 2024091777A5 JP 2024066552 A JP2024066552 A JP 2024066552A JP 2024066552 A JP2024066552 A JP 2024066552A JP 2024091777 A5 JP2024091777 A5 JP 2024091777A5
- Authority
- JP
- Japan
- Prior art keywords
- human subject
- agent
- antibody
- tau
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 | |
| US63/273,216 | 2021-10-29 | ||
| JP2022172479A JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Division JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024091777A JP2024091777A (ja) | 2024-07-05 |
| JP2024091777A5 true JP2024091777A5 (enExample) | 2025-11-04 |
Family
ID=84367272
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Active JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2024066552A Pending JP2024091777A (ja) | 2021-10-29 | 2024-04-17 | インターロイキン－３４を標的とする化合物及び方法 |
| JP2025005276A Pending JP2025063187A (ja) | 2021-10-29 | 2025-01-15 | インターロイキン－３４を標的とする化合物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172479A Active JP7622019B2 (ja) | 2021-10-29 | 2022-10-27 | インターロイキン－３４を標的とする化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005276A Pending JP2025063187A (ja) | 2021-10-29 | 2025-01-15 | インターロイキン－３４を標的とする化合物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (enExample) |
| EP (1) | EP4423127A1 (enExample) |
| JP (3) | JP7622019B2 (enExample) |
| KR (1) | KR20240099349A (enExample) |
| CN (1) | CN118475610A (enExample) |
| AR (1) | AR127484A1 (enExample) |
| AU (1) | AU2022376940A1 (enExample) |
| CA (1) | CA3236555A1 (enExample) |
| CL (1) | CL2024001303A1 (enExample) |
| CO (1) | CO2024005417A2 (enExample) |
| CR (1) | CR20240170A (enExample) |
| DO (1) | DOP2024000076A (enExample) |
| EC (1) | ECSP24032906A (enExample) |
| IL (1) | IL312380A (enExample) |
| MX (1) | MX2024005153A (enExample) |
| PE (1) | PE20241471A1 (enExample) |
| TW (1) | TW202336034A (enExample) |
| WO (1) | WO2023076995A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4472679A1 (en) * | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5828762B2 (ja) | 2008-07-21 | 2015-12-09 | プロビオドルグ エージー | 診断用抗体アッセイ |
| EP2576617B1 (en) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| LT3042917T (lt) | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| BR112014018961A8 (pt) | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| KR20170031245A (ko) | 2014-07-28 | 2017-03-20 | 노그라 파마 리미티드 | 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물 |
| WO2016097420A1 (en) | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| EP3302552A1 (en) | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10988529B2 (en) * | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3758736B1 (en) | 2018-03-02 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Il-34 for use in a method of treating retinal inflammation and neurodegeneration |
| EA202192888A1 (ru) | 2019-05-31 | 2022-03-23 | Эли Лилли Энд Компани | Соединения и способы нацеливания на тау человека |
| AR121898A1 (es) * | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022002524A5 (enExample) | ||
| CN104023743B (zh) | 抗体制剂和方法 | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2018535648A5 (enExample) | ||
| CN112654640B (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| JP2005501102A (ja) | 炎症性腸疾患の経口免疫グロブリン治療 | |
| JP2024091777A5 (enExample) | ||
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| WO2022204244A1 (en) | Human ccl28 antibodies | |
| WO2022090169A1 (en) | Method of safe administration of anti-tau antibody | |
| JP2025063187A5 (enExample) | ||
| IL312380A (en) | Compounds and methods targeting interleukin-34 | |
| KR20240035835A (ko) | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 | |
| JP7377185B2 (ja) | 抗ヒトｔｌｒ７抗体 | |
| US20250090659A1 (en) | Combination therapy with an anti-cd19 antibody and parsaclisib | |
| US20130004516A1 (en) | Drug for inflammatory bowel disease | |
| WO2024246085A1 (en) | Therapeutic use of bispecific anti-abeta/tfr antibodies | |
| US20240109977A1 (en) | Anti-cd38 antibodies and their uses | |
| TWI879859B (zh) | 急性期之視神經脊髓炎之預防或治療劑 | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| JP2024525870A (ja) | 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療 | |
| JP7789368B2 (ja) | 炎症性腸疾患に対する治療用抗体 | |
| EP4375296A1 (en) | An a-fabp neutralizing monoclonal antibody and preparation method and use thereof | |
| TWI887333B (zh) | 失智症之預防或治療劑 | |
| JPWO2022135467A5 (enExample) |